[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuNgwdmBsNO9t_exCWAKfnIwfTf9l-CLG1PlSmrA9yyo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Centro Cardiologico Monzino",[4],66,false,18,2,69071,1,56,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Heart Failure",9,{"name":18,"count":19},"Coronary Artery Disease",5,{"name":21,"count":22},"Cardiovascular Diseases",3,{"name":24,"count":22},"Cardiopulmonary Exercise Test",{"name":26,"count":22},"Atrial Fibrillation",{"name":28,"count":9},"Myocardial Ischemia",{"name":30,"count":9},"Depression",{"name":32,"count":9},"Mitral Valve Prolapse",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06922994","Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)","2026-11-30","Atorvastatin 80 mg\u002Fday",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,70,97,122,140,158,185,203,228,252,280,298,323,348],{"intervention":38,"totalTrials":11,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":64,"PHASE4":66,"NA":68},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":11,"soonestReadout":37},[56],{"nctId":35,"briefTitle":36,"status":57,"phases":58,"primaryCompletion":37,"completion":37,"start":59,"enrollment":60,"conditions":61,"interventions":63},"RECRUITING",[42],"2025-03-31",102,[62],"Arrhythmogenic Cardiomyopathy",[38],{"trials":65,"activeCount":51},[],{"trials":67,"activeCount":51},[],{"trials":69,"activeCount":51},[],{"intervention":71,"totalTrials":11,"cells":72},"acetazolamide",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":95},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"NCT00517426","Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure","COMPLETED",[44],"2011-07","2012-08","2007-07",20,[93],"Chronic Heart Failure",[71],{"trials":96,"activeCount":51},[],{"intervention":98,"totalTrials":11,"cells":99},"carvedilol",{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":120},{"trials":101,"activeCount":51},[],{"trials":103,"activeCount":51},[],{"trials":105,"activeCount":51},[],{"trials":107,"activeCount":51},[],{"trials":109,"activeCount":51},[110],{"nctId":111,"briefTitle":112,"status":86,"phases":113,"completion":114,"start":90,"enrollment":115,"conditions":116,"interventions":117},"NCT00517725","Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure",[44],"2010-05",60,[93],[98,118,119],"bisoprolol","Nebivolol",{"trials":121,"activeCount":51},[],{"intervention":118,"totalTrials":11,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":138},{"trials":125,"activeCount":51},[],{"trials":127,"activeCount":51},[],{"trials":129,"activeCount":51},[],{"trials":131,"activeCount":51},[],{"trials":133,"activeCount":51},[134],{"nctId":111,"briefTitle":112,"status":86,"phases":135,"completion":114,"start":90,"enrollment":115,"conditions":136,"interventions":137},[44],[93],[98,118,119],{"trials":139,"activeCount":51},[],{"intervention":119,"totalTrials":11,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":51},[],{"trials":145,"activeCount":51},[],{"trials":147,"activeCount":51},[],{"trials":149,"activeCount":51},[],{"trials":151,"activeCount":51},[152],{"nctId":111,"briefTitle":112,"status":86,"phases":153,"completion":114,"start":90,"enrollment":115,"conditions":154,"interventions":155},[44],[93],[98,118,119],{"trials":157,"activeCount":51},[],{"intervention":159,"totalTrials":11,"cells":160},"Ropivacaine",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":183},{"trials":162,"activeCount":51},[],{"trials":164,"activeCount":51},[],{"trials":166,"activeCount":51},[],{"trials":168,"activeCount":51},[],{"trials":170,"activeCount":51},[171],{"nctId":172,"briefTitle":173,"status":86,"phases":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":181},"NCT00552864","Comparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthesia",[44],"2005-06","2003-01",61,[179,180],"Coronary Artery Bypass","Epidural Anesthesia",[159,182],"Levobupivacaine",{"trials":184,"activeCount":51},[],{"intervention":182,"totalTrials":11,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":201},{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[197],{"nctId":172,"briefTitle":173,"status":86,"phases":198,"completion":175,"start":176,"enrollment":177,"conditions":199,"interventions":200},[44],[179,180],[159,182],{"trials":202,"activeCount":51},[],{"intervention":204,"totalTrials":11,"cells":205},"Levosimendan",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":226},{"trials":207,"activeCount":51},[],{"trials":209,"activeCount":51},[],{"trials":211,"activeCount":51},[],{"trials":213,"activeCount":51},[],{"trials":215,"activeCount":51},[216],{"nctId":217,"briefTitle":218,"status":86,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT02261948","Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)",[44],"2014-09","2014-12","2012-09",42,[15],[204],{"trials":227,"activeCount":51},[],{"intervention":229,"totalTrials":11,"cells":230},"Indacaterol",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":248,"NA":250},{"trials":232,"activeCount":51},[],{"trials":234,"activeCount":51},[],{"trials":236,"activeCount":51},[],{"trials":238,"activeCount":51},[239],{"nctId":240,"briefTitle":241,"status":86,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":247},"NCT02598505","Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation",[43],"2016-11","2015-09",44,[15],[229],{"trials":249,"activeCount":51},[],{"trials":251,"activeCount":51},[],{"intervention":253,"totalTrials":11,"cells":254},"Furosemide and matched saline hydration",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":276,"NA":278},{"trials":256,"activeCount":51},[],{"trials":258,"activeCount":51},[],{"trials":260,"activeCount":51},[],{"trials":262,"activeCount":51},[263],{"nctId":264,"briefTitle":265,"status":266,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT00702728","Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention","UNKNOWN",[43],"2009-06","2009-12","2008-06",120,[273],"Contrast Induced Nephropathy",[253,275],"isotonic saline solution",{"trials":277,"activeCount":51},[],{"trials":279,"activeCount":51},[],{"intervention":275,"totalTrials":11,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":294,"NA":296},{"trials":283,"activeCount":51},[],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[290],{"nctId":264,"briefTitle":265,"status":266,"phases":291,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":292,"interventions":293},[43],[273],[253,275],{"trials":295,"activeCount":51},[],{"trials":297,"activeCount":51},[],{"intervention":299,"totalTrials":11,"cells":300},"Acetyl cysteine",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":302,"activeCount":51},[],{"trials":304,"activeCount":51},[],{"trials":306,"activeCount":51},[307],{"nctId":308,"briefTitle":309,"status":86,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT04154982","N-Acetylcysteine Protection Against Radiation Induced Cellular Damage",[42],"2024-12-02","2020-09-02",181,[315],"Cardiac Arrhythmia",[299],{"trials":318,"activeCount":51},[],{"trials":320,"activeCount":51},[],{"trials":322,"activeCount":51},[],{"intervention":324,"totalTrials":11,"cells":325},"Aspirin",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[332],{"nctId":333,"briefTitle":334,"status":266,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":341},"NCT01466452","Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and\u002For Aortic Valve Surgery",[42],"2013-09","2011-09",99,[340],"Coronary Arteriosclerosis",[324,324,324],{"trials":343,"activeCount":51},[],{"trials":345,"activeCount":51},[],{"trials":347,"activeCount":51},[],{"intervention":349,"totalTrials":11,"cells":350},"Sacubitril-Valsartan",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[],{"trials":356,"activeCount":51},[],{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[],{"trials":362,"activeCount":51},[363],{"nctId":364,"briefTitle":365,"status":86,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT04434170","Effects of Sacubitril\u002FValsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure",[],"2020-11-30","2021-12-15","2018-10-15",112,[15],[349]]